The present study is the first to demonstrate that systemically administered MSCs could prevent the muscle wasting associated with HFD-induced obesity, by preventing the decreased MHC levels, increased UPP activity, increased myonuclear apoptosis, and oxidative stress. This evidence concerns the gene HLA-C and obesity due to melanocortin 4 receptor deficiency.